메뉴 건너뛰기




Volumn 16, Issue 5, 2009, Pages 347-356

Oral anticoagulation with factor Xa and thrombin inhibitors: On the threshold of change

Author keywords

Apixaban; Dabigatran; Factor Xa; Oral anticoagulants; Rivaroxaban; Thrombin

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DABIGATRAN ETEXILATE; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; THIENOPYRIDINE DERIVATIVE; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; WARFARIN; XARELTO;

EID: 69549097721     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32832ea2d7     Document Type: Review
Times cited : (29)

References (47)
  • 1
    • 19344361965 scopus 로고    scopus 로고
    • New anticoagulants and their potential impact on the treatment of thromboembolic disease
    • Ansell J. New anticoagulants and their potential impact on the treatment of thromboembolic disease. Curr Hematol Rep 2004; 3:357-362.
    • (2004) Curr Hematol Rep , vol.3 , pp. 357-362
    • Ansell, J.1
  • 2
    • 55249089038 scopus 로고    scopus 로고
    • New anticoagulants
    • Bauer KA. New anticoagulants. Curr Opin Hematol 2008; 15:509-515.
    • (2008) Curr Opin Hematol , vol.15 , pp. 509-515
    • Bauer, K.A.1
  • 3
    • 69549104053 scopus 로고    scopus 로고
    • Bristol-Myers Squibb Company, approved by the FDA, August
    • Coumadin medication pamphlet guide. Bristol-Myers Squibb Company, approved by the FDA, August 2007.
    • (2007) Coumadin Medication Pamphlet Guide
  • 5
    • 58149401862 scopus 로고    scopus 로고
    • Apixaban, an oral direct Factor Xa inhibitor: Awaiting the verdict
    • Carreiro J, Ansell J. Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict. Expert Opin Investig Drugs 2008; 17:1937-1945.
    • (2008) Expert Opin Investig Drugs , vol.17 , pp. 1937-1945
    • Carreiro, J.1    Ansell, J.2
  • 6
    • 40749131754 scopus 로고    scopus 로고
    • New anticoagulants for treatment of venous thromboembolism
    • Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 2008; 28:380-386.
    • (2008) Arterioscler Thromb Vasc Biol , vol.28 , pp. 380-386
    • Gross, P.L.1    Weitz, J.I.2
  • 8
    • 69549106868 scopus 로고    scopus 로고
    • Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates
    • abstract 3825
    • Gruber A, Marzec U, Buetehorn U, et al. Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates. ASH annual meeting abstracts presented November 16, 2008 [abstract 3825].
    • ASH Annual Meeting Abstracts Presented November 16, 2008
    • Gruber, A.1    Marzec, U.2    Buetehorn, U.3
  • 9
    • 0035128503 scopus 로고    scopus 로고
    • Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range
    • Hirsch J, Dalen J, Anderson D, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimum therapeutic range. Chest 2001; 119 (Suppl):8S-21S. (Pubitemid 32154192)
    • (2001) Chest , vol.119 , Issue.1 SUPPL.
    • Hirsh, J.1    Dalen, J.E.2    Anderson, D.R.3    Poller, L.4    Bussey, H.5    Ansell, J.6    Deykin, D.7
  • 10
    • 0035128599 scopus 로고    scopus 로고
    • Antithrombotic therapy in atrial fibrillation
    • Albers GW, Dalen J, Laupacis A, et al. Antithrombotic therapy in atrial fibrillation. Chest 2001; 119:194S-206S.
    • (2001) Chest , vol.119
    • Albers, G.W.1    Dalen, J.2    Laupacis, A.3
  • 11
    • 34250700118 scopus 로고    scopus 로고
    • Factor Xa or thrombin: Is factor Xa a better target?
    • Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost 2007; Suppl 1:60-64.
    • (2007) J Thromb Haemost , Issue.SUPPL. 1 , pp. 60-64
    • Ansell, J.1
  • 12
    • 34249310268 scopus 로고    scopus 로고
    • Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases
    • DOI 10.1161/ATVBAHA.107.139402
    • Turpie AG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007; 27:1238-1247. (Pubitemid 46809411)
    • (2007) Arteriosclerosis, Thrombosis, and Vascular Biology , vol.27 , Issue.6 , pp. 1238-1247
    • Turpie, A.G.G.1
  • 13
    • 33751559902 scopus 로고    scopus 로고
    • A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement
    • ODIXa-HIP Study Investigators
    • ODIXa-HIP Study Investigators: Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006; 114: 2374-2381.
    • (2006) Circulation , vol.114 , pp. 2374-2381
    • Eriksson, B.I.1    Borris, L.C.2    Dahl, O.E.3
  • 14
    • 33644867218 scopus 로고    scopus 로고
    • Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement
    • ODIXa-HIP Study Investigators
    • ODIXa-HIP Study Investigators: Eriksson BI, Borris L, Dahl OE, et al. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006; 4:121-128.
    • (2006) J Thromb Haemost , vol.4 , pp. 121-128
    • Eriksson, B.I.1    Borris, L.2    Dahl, O.E.3
  • 15
    • 28444474155 scopus 로고    scopus 로고
    • BAY 59-7939: An oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase-II dose-ranging study
    • ODIXa-Knee Study Group
    • ODIXa-Knee Study Group: Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase-II dose-ranging study. J Thromb Haemost 2005; 3:2479-2486.
    • (2005) J Thromb Haemost , vol.3 , pp. 2479-2486
    • Turpie, A.G.1    Fisher, W.D.2    Bauer, K.A.3
  • 16
    • 34250645346 scopus 로고    scopus 로고
    • Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studies
    • Fisher WD, Eriksson BI, Bauer KA, et al. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb Haemost 2007; 97:931-937.
    • (2007) Thromb Haemost , vol.97 , pp. 931-937
    • Fisher, W.D.1    Eriksson, B.I.2    Bauer, K.A.3
  • 17
    • 34447317298 scopus 로고    scopus 로고
    • Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): The ODIXa-DVT (oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study
    • ODIXa-DVT Study Investigators
    • ODIXa-DVT Study Investigators: Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 2007; 116:180-187.
    • (2007) Circulation , vol.116 , pp. 180-187
    • Agnelli, G.1    Gallus, A.2    Goldhaber, S.Z.3
  • 18
    • 45949103416 scopus 로고    scopus 로고
    • Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
    • RECORD3 Investigators This phase III study found rivaroxaban was superior to European enoxaparin 40 mg regimens for 10-14 days of thromboembolism prophylaxis following total knee replacement
    • RECORD3 Investigators: Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358:2776-2786. This phase III study found rivaroxaban was superior to European enoxaparin 40 mg regimens for 10-14 days of thromboembolism prophylaxis following total knee replacement.
    • (2008) N Engl J Med , vol.358 , pp. 2776-2786
    • Lassen, M.R.1    Ageno, W.2    Borris, L.C.3
  • 19
    • 69549109243 scopus 로고    scopus 로고
    • Rivaroxaban: An oral, direct Factor Xa inhibitor versus enoxaparin for thromboprophylaxis after total knee replacement
    • RECORD4 Study Investigators: presented by on behalf of abstract 35. This phase III study found rivaroxaban was superior to North American enoxaparin 30 mg b.i.d. regimens for 10-14 days thromboembolism prophylaxis following total knee replacement
    • RECORD4 Study Investigators: presented by Turpie AG on behalf of Bauer KA, Berkowitz SD, Cushner FD, et al. Rivaroxaban: an oral, direct Factor Xa inhibitor versus enoxaparin for thromboprophylaxis after total knee replacement. ASH annual meeting abstracts presented December 7, 2008 [abstract 35]. This phase III study found rivaroxaban was superior to North American enoxaparin 30 mg b.i.d. regimens for 10-14 days thromboembolism prophylaxis following total knee replacement.
    • ASH Annual Meeting Abstracts Presented December 7, 2008
    • Turpie, A.G.1    Bauer, K.A.2    Berkowitz, S.D.3    Cushner, F.D.4
  • 20
    • 45949099359 scopus 로고    scopus 로고
    • Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
    • RECORD1 Study Group This phase III study found rivaroxaban superior to European enoxaparin regimens 40 mg for extended (35 days) thromboembolism prophylaxis following total hip replacement
    • RECORD1 Study Group: Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358:2765-2775. This phase III study found rivaroxaban superior to European enoxaparin regimens 40 mg for extended (35 days) thromboembolism prophylaxis following total hip replacement.
    • (2008) N Engl J Med , vol.358 , pp. 2765-2775
    • Eriksson, B.I.1    Borris, L.C.2    Friedman, R.J.3
  • 21
    • 46049106502 scopus 로고    scopus 로고
    • Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomized controlled trial
    • RECORD2 Investigators: This phase III study found an extended course of anticoagulation with rivaroxaban was superior to short course of European enoxaparin regimens for thromboembolism prophylaxis following total hip replacement
    • RECORD2 Investigators: Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial. Lancet 2008; 372:31-39. This phase III study found an extended course of anticoagulation with rivaroxaban was superior to short course of European enoxaparin regimens for thromboembolism prophylaxis following total hip replacement.
    • (2008) Lancet , vol.372 , pp. 31-39
    • Kakkar, A.K.1    Brenner, B.2    Dahl, O.E.3
  • 22
    • 69549119444 scopus 로고    scopus 로고
    • A pooled analysis of four pivotal studies of rivaroxaban for the prevention of venous thromboembolism after orthopedic surgery: Effect on symptomatic venous thromboembolism, death, and bleeding
    • abstract 36. This meta-analysis of RECORD trials in 12 729 patients found rivaroxaban superior to enoxaparin in VTE prevention following orthopedic surgery
    • Turpie A, Lassen M, Kakkar A, et al. A pooled analysis of four pivotal studies of rivaroxaban for the prevention of venous thromboembolism after orthopedic surgery: effect on symptomatic venous thromboembolism, death, and bleeding. ASH annual meeting abstracts presented November 16, 2008 [abstract 36]. This meta-analysis of RECORD trials in 12 729 patients found rivaroxaban superior to enoxaparin in VTE prevention following orthopedic surgery.
    • ASH Annual Meeting Abstracts Presented November 16, 2008
    • Turpie, A.1    Lassen, M.2    Kakkar, A.3
  • 23
    • 69549128707 scopus 로고    scopus 로고
    • Effects of age, weight, gender, and renal function in a pooled analysis of four phase-III studies of rivaroxaban for prevention of venous thromboembolism after major orthopedic surgery
    • abstract 436
    • Bauer K, Homering M, Berkowitz S. Effects of age, weight, gender, and renal function in a pooled analysis of four phase-III studies of rivaroxaban for prevention of venous thromboembolism after major orthopedic surgery. ASH annual meeting abstracts presented November 16, 2008 [abstract 436].
    • ASH Annual Meeting Abstracts Presented November 16, 2008
    • Bauer, K.1    Homering, M.2    Berkowitz, S.3
  • 24
    • 69549085594 scopus 로고    scopus 로고
    • A pooled analysis of four pivotal studies of rivaroxaban for the prevention of venous thromboembolism after orthopedic surgery: Effects of specified co-medications
    • abstract 1986
    • Eriksson B, Turpie A, Lassen M, et al. A pooled analysis of four pivotal studies of rivaroxaban for the prevention of venous thromboembolism after orthopedic surgery: effects of specified co-medications. ASH annual meeting abstracts presented November 16, 2008 [abstract 1986].
    • ASH Annual Meeting Abstracts Presented November 16, 2008
    • Eriksson, B.1    Turpie, A.2    Lassen, M.3
  • 25
    • 53849123533 scopus 로고    scopus 로고
    • A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: The Einstein-DVT Dose-Ranging Study
    • Einstein-DVT Dose-Ranging Study investigators: This pivotal phase II study recommended rivaroxaban 20mg b.i.d. for initial VTE treatment for 3 weeks followed by 20mg once daily to be evaluated in phase III studies
    • Einstein-DVT Dose-Ranging Study investigators: Buller HR, Lensing AW, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008; 112:2242-2247. This pivotal phase II study recommended rivaroxaban 20mg b.i.d. for initial VTE treatment for 3 weeks followed by 20mg once daily to be evaluated in phase III studies.
    • (2008) Blood , vol.112 , pp. 2242-2247
    • Buller, H.R.1    Lensing, A.W.2    Prins, M.H.3
  • 26
    • 69549117615 scopus 로고    scopus 로고
    • Anti-Xa therapy to lower cardiovascular events in addition to aspirin with or without thienopyridine therapy in subjects with acute coronary syndrome: Thrombolysis in myocardial infarction 46 trial
    • ATLAS TIMI 46 Study group: This pivotal phase II study recommended rivaroxaban 2.5-5mg b.i.d. for ACS prevention in the phase III ATLAS-2 TIMI 51 trial
    • ATLAS TIMI 46 Study group: Gibson CM, Mega JL, Hammett CJ, et al. Anti-Xa therapy to lower cardiovascular events in addition to aspirin with or without thienopyridine therapy in subjects with acute coronary syndrome: thrombolysis in myocardial infarction 46 trial. AHA scientific session presented November 10, 2008. This pivotal phase II study recommended rivaroxaban 2.5-5mg b.i.d. for ACS prevention in the phase III ATLAS-2 TIMI 51 trial.
    • AHA Scientific Session Presented November 10, 2008
    • Gibson, C.M.1    Mega, J.L.2    Hammett, C.J.3
  • 27
    • 36348978071 scopus 로고    scopus 로고
    • The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement
    • DOI 10.1111/j.1538-7836.2007.02764.x
    • Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007; 5:2368-2375. (Pubitemid 350154345)
    • (2007) Journal of Thrombosis and Haemostasis , vol.5 , Issue.12 , pp. 2368-2375
    • Lassen, M.R.1    Davidson, B.L.2    Gallus, A.3    Pineo, G.4    Ansell, J.5    Deitchman, D.6
  • 28
    • 69549127144 scopus 로고    scopus 로고
    • Randomized double-blind comparison of apixaban with enoxaparin for thromboprophylaxis after knee replacement: The ADVANCE-1 trial
    • abstract 31. This phase III trial found apixaban to be noninferior to enoxaparin to enoxaparin with less bleeding risk for VTE prevention
    • Lassen M, Gallus A, Pineo G, Raskob G. Randomized double-blind comparison of apixaban with enoxaparin for thromboprophylaxis after knee replacement: the ADVANCE-1 trial. ASH annual meeting abstracts presented November 16, 2008 [abstract 31]. This phase III trial found apixaban to be noninferior to enoxaparin to enoxaparin with less bleeding risk for VTE prevention.
    • ASH Annual Meeting Abstracts Presented November 16, 2008
    • Lassen, M.1    Gallus, A.2    Pineo, G.3    Raskob, G.4
  • 29
    • 47649098524 scopus 로고    scopus 로고
    • Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. the Botticelli DVT dose-ranging study
    • DOI 10.1111/j.1538-7836.2008.03054.x
    • Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008; 6:1313-1318. This pivotal phase II study recommended apixaban 10mg b.i.d. for acute VTE treatment and 5mg b.i.d. for chronic uses in phase III AMPLIFY trials. (Pubitemid 352016310)
    • (2008) Journal of Thrombosis and Haemostasis , vol.6 , Issue.8 , pp. 1313-1318
    • Buller, H.1    Deitchman, D.2    Prins, M.3    Segers, A.4
  • 30
    • 69549109242 scopus 로고    scopus 로고
    • Safety of the factor Xa inhibitor, apixaban, in combination with antiplatelet therapy after acute coronary syndromes: Results from the APPRAISE-1 dose guiding trial
    • APPRAISE Investigators: This pivotal phase II study recommended apixaban 2.5-5mg b.i.d. or 5-10mg daily for further phase III studies evaluating ACS prevention in patients who had recently experienced an ACS event
    • APPRAISE Investigators: Alexander JH, Wallentin L, et al. Safety of the factor Xa inhibitor, apixaban, in combination with antiplatelet therapy after acute coronary syndromes: results from the APPRAISE-1 dose guiding trial. European Society of Cardiology meeting presented September 2, 2008. This pivotal phase II study recommended apixaban 2.5-5mg b.i.d. or 5-10mg daily for further phase III studies evaluating ACS prevention in patients who had recently experienced an ACS event.
    • European Society of Cardiology Meeting Presented September 2, 2008
    • Alexander, J.H.1    Wallentin, L.2
  • 31
    • 41949084883 scopus 로고    scopus 로고
    • New anticoagulant agents: Direct thrombin inhibitors
    • Nutescu EA, Shapiro NL, Chevalier A. New anticoagulant agents: direct thrombin inhibitors. Cardiol Clin 2008; 26:169-187.
    • (2008) Cardiol Clin , vol.26 , pp. 169-187
    • Nutescu, E.A.1    Shapiro, N.L.2    Chevalier, A.3
  • 33
    • 17644409026 scopus 로고    scopus 로고
    • A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: The BISTRO II randomized trial
    • BISTRO II Study Group
    • BISTRO II Study Group: Eriksson BI, Dahl OE, Büller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3:103-111.
    • (2005) J Thromb Haemost , vol.3 , pp. 103-111
    • Eriksson, B.I.1    Dahl, O.E.2    Büller, H.R.3
  • 34
    • 35449007749 scopus 로고    scopus 로고
    • Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial
    • RE-MODEL Study Group
    • RE-MODEL Study Group: Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5:2178-2185.
    • (2007) J Thromb Haemost , vol.5 , pp. 2178-2185
    • Eriksson, B.I.1    Dahl, O.E.2    Rosencher, N.3
  • 35
    • 57649123692 scopus 로고    scopus 로고
    • Oral thrombin inhibitor dabigatran etexilate vs. North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery
    • RE-MOBILIZE Writing Committee: This phase III trial compared dagibatrin to the North American enoxaparin 30mg regimen, which is administered twice daily
    • RE-MOBILIZE Writing Committee: Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs. North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24:1-9. This phase III trial compared dagibatrin to the North American enoxaparin 30mg regimen, which is administered twice daily.
    • (2009) J Arthroplasty , vol.24 , pp. 1-9
    • Ginsberg, J.S.1    Davidson, B.L.2    Comp, P.C.3
  • 36
    • 34548575058 scopus 로고    scopus 로고
    • Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, noninferiority trial
    • RE-NOVATE Study Group
    • RE-NOVATE Study Group: Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, noninferiority trial. Lancet 2007; 370:949-956.
    • (2007) Lancet , vol.370 , pp. 949-956
    • Eriksson, B.I.1    Dahl, O.E.2    Rosencher, N.3
  • 37
    • 60449115366 scopus 로고    scopus 로고
    • Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis
    • This meta-analysis of phase III trials evaluating dabigatran etexilate in VTE prevention following orthopedic surgery, included 8185 patients and found no difference in VTE incidence and bleeding events for dabigatran and enoxaparin
    • Wolowacz SE, Roskell NS, Plumb JM, et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009; 101:77-85. This meta-analysis of phase III trials evaluating dabigatran etexilate in VTE prevention following orthopedic surgery, included 8185 patients and found no difference in VTE incidence and bleeding events for dabigatran and enoxaparin.
    • (2009) Thromb Haemost , vol.101 , pp. 77-85
    • Wolowacz, S.E.1    Roskell, N.S.2    Plumb, J.M.3
  • 38
    • 69549115491 scopus 로고    scopus 로고
    • Efficacy and safety profile of dabigatran etexilate compared with enoxaparin in primary venous thromboembolism prevention after total knee or hip replacement surgery in patients over 75 years
    • abstract 437
    • Dahl O, Kurth A, Rosencher N, et al. Efficacy and safety profile of dabigatran etexilate compared with enoxaparin in primary venous thromboembolism prevention after total knee or hip replacement surgery in patients over 75 years. ASH annual meeting abstracts presented November 16, 2008 [abstract 437].
    • ASH Annual Meeting Abstracts Presented November 16, 2008
    • Dahl, O.1    Kurth, A.2    Rosencher, N.3
  • 40
    • 45949083155 scopus 로고    scopus 로고
    • New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    • American College of Chest Physicians 8th ed..
    • Weitz JI, Hirsh J, Samama MM, American College of Chest Physicians. New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.). Chest 2008; 133 (6 Suppl):234S-256S.
    • (2008) Chest , vol.133 , Issue.6 SUPPL.
    • Weitz, J.I.1    Hirsh, J.2    Samama, M.M.3
  • 41
    • 43149115406 scopus 로고    scopus 로고
    • Current and future prospects for anticoagulant therapy: Inhibitors of factor Xa and factor IIa
    • Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost 2008; 34:39-57.
    • (2008) Semin Thromb Hemost , vol.34 , pp. 39-57
    • Harenberg, J.1    Wehling, M.2
  • 42
    • 38049160266 scopus 로고    scopus 로고
    • New oral Xa and IIa inhibitors: Updates on clinical trial results
    • Haas S. New oral Xa and IIa inhibitors: updates on clinical trial results. J Thromb Thrombolysis 2008; 25:52-60.
    • (2008) J Thromb Thrombolysis , vol.25 , pp. 52-60
    • Haas, S.1
  • 43
    • 33748590510 scopus 로고    scopus 로고
    • Emerging anticoagulants for the treatment of venous thromboembolism
    • DOI 10.1160/TH06-05-0234
    • Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost 2006; 96:274-284. (Pubitemid 44377809)
    • (2006) Thrombosis and Haemostasis , vol.96 , Issue.3 , pp. 274-284
    • Weitz, J.I.1
  • 46
    • 69549143141 scopus 로고    scopus 로고
    • Rivaroxaban for prevention of venous thromboembolism after total knee replacement: Impact on healthcare costs based on RECORD4 study
    • abstract 1289
    • Kwong L, Sengupta N, Lees M. Rivaroxaban for prevention of venous thromboembolism after total knee replacement: impact on healthcare costs based on RECORD4 study. ASH annual meeting abstracts presented November 16, 2008 [abstract 1289].
    • ASH Annual Meeting Abstracts Presented November 16, 2008
    • Kwong, L.1    Sengupta, N.2    Lees, M.3
  • 47
    • 69549089177 scopus 로고    scopus 로고
    • Will Rivaroxaban be costeffective for prevention of venous thromboembolism after total hip replacement in US patients?
    • abstract 129
    • Kwong L, Diamantopoulos A, Forster F, et al. Will Rivaroxaban be costeffective for prevention of venous thromboembolism after total hip replacement in US patients? ASH annual meeting abstracts presented November 16, 2008 [abstract 129].
    • ASH Annual Meeting Abstracts Presented November 16, 2008
    • Kwong, L.1    Diamantopoulos, A.2    Forster, F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.